The independent National Institute for Clinical Excellence provisionally rejected Switzerland-based Novartis' Tasigna and U.S.-based Bristol-Myers Squibb' Sprycel for chronic myeloid leukaemia in patients who are intolerant to imatinib (an older Novartis drug whose brand name is Gleevec) saying evidence to support their effectiveness was "very poor" and their cost was "extremely high". The independent agency also rejected Novartis's tumor treatment Afinitor as a second-line treatment for advanced kidney cancer in a draft ruling.
via advfn.com
No comments:
Post a Comment